Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1971 1
1976 1
1979 2
1980 1
1982 1
1984 4
1985 1
1986 4
1987 7
1988 4
1989 7
1990 5
1991 10
1992 5
1993 15
1994 11
1995 8
1996 10
1997 11
1998 15
1999 11
2000 18
2001 10
2002 8
2003 11
2004 9
2005 13
2006 12
2007 22
2008 23
2009 16
2010 15
2011 43
2012 36
2013 49
2014 36
2015 55
2016 53
2017 48
2018 35
2019 50
2020 60
2021 76
2022 66
2023 71
2024 68

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

936 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: prat a. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. Rugo HS, et al. Among authors: prat a. Lancet Oncol. 2021 Apr;22(4):489-498. doi: 10.1016/S1470-2045(21)00034-6. Lancet Oncol. 2021. PMID: 33794206 Clinical Trial.
The Multifaceted Biology of PCSK9.
Seidah NG, Prat A. Seidah NG, et al. Among authors: prat a. Endocr Rev. 2022 May 12;43(3):558-582. doi: 10.1210/endrev/bnab035. Endocr Rev. 2022. PMID: 35552680 Free PMC article. Review.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. Cardoso F, et al. Among authors: prat a. Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23. Ann Oncol. 2020. PMID: 32979513 Free PMC article. No abstract available.
Barcoded viral tracing of single-cell interactions in central nervous system inflammation.
Clark IC, Gutiérrez-Vázquez C, Wheeler MA, Li Z, Rothhammer V, Linnerbauer M, Sanmarco LM, Guo L, Blain M, Zandee SEJ, Chao CC, Batterman KV, Schwabenland M, Lotfy P, Tejeda-Velarde A, Hewson P, Manganeli Polonio C, Shultis MW, Salem Y, Tjon EC, Fonseca-Castro PH, Borucki DM, Alves de Lima K, Plasencia A, Abate AR, Rosene DL, Hodgetts KJ, Prinz M, Antel JP, Prat A, Quintana FJ. Clark IC, et al. Among authors: prat a. Science. 2021 Apr 23;372(6540):eabf1230. doi: 10.1126/science.abf1230. Science. 2021. PMID: 33888612 Free PMC article.
AXL - a new player in resistance to HER2 blockade.
Adam-Artigues A, Arenas EJ, Arribas J, Prat A, Cejalvo JM. Adam-Artigues A, et al. Among authors: prat a. Cancer Treat Rev. 2023 Dec;121:102639. doi: 10.1016/j.ctrv.2023.102639. Epub 2023 Oct 7. Cancer Treat Rev. 2023. PMID: 37864955 Free article. Review.
Droplet-based forward genetic screening of astrocyte-microglia cross-talk.
Wheeler MA, Clark IC, Lee HG, Li Z, Linnerbauer M, Rone JM, Blain M, Akl CF, Piester G, Giovannoni F, Charabati M, Lee JH, Kye YC, Choi J, Sanmarco LM, Srun L, Chung EN, Flausino LE, Andersen BM, Rothhammer V, Yano H, Illouz T, Zandee SEJ, Daniel C, Artis D, Prinz M, Abate AR, Kuchroo VK, Antel JP, Prat A, Quintana FJ. Wheeler MA, et al. Among authors: prat a. Science. 2023 Mar 10;379(6636):1023-1030. doi: 10.1126/science.abq4822. Epub 2023 Mar 9. Science. 2023. PMID: 36893254 Free PMC article.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EP. Tolaney SM, et al. Among authors: prat a. Lancet Oncol. 2023 Mar;24(3):273-285. doi: 10.1016/S1470-2045(23)00051-7. Lancet Oncol. 2023. PMID: 36858723 Clinical Trial.
936 results